SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio’s common stock has been approved for ...

Based on data from TipRanks, one Wall Street analyst has a Buy rating on the stock and a 12-month price forecast of $6. Moreover, three analysts have an average “Strong Buy” rating on Ibio ...

SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio’s common stock has been approved for listing on ...

The Company's common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025. Martin Brenner, Ph.D., DVM, iBio's CEO and Chief Scientific Officer, commented,“We ...

Based on data from TipRanks, one Wall Street analyst has a Buy rating on the stock and a 12-month price forecast of $6. Moreover, three analysts have an average “Strong Buy” rating on Ibio ...

Shares of iBio Inc. IBIO climbed 13.08% to $3.89 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.37% to ...

In this article, we are going to take a look at where Ibio, Inc. (NYSEAMERICAN ... this year we used Insider Monkey’s insider trading stock screener and looked for stocks with at least five ...

Shares of iBio Inc. IBIO soared 34.31% to $5.05 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 2.78% to ...